Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Regeneron Pharmaceuticals (NQ: REGN ) 1,044.66 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 86 Open 1,044.66 Bid (Size) 1,002.00 (1) Ask (Size) 1,057.00 (1) Prev. Close 1,044.66 Today's Range 1,044.66 - 1,044.66 52wk Range 688.52 - 1,081.17 Shares Outstanding 91,779,465 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD Today 1:00 EDT From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Looking Into Regeneron Pharmaceuticals's Recent Short Interest July 02, 2024 Via Benzinga Performance YTD +15.43% +15.43% 1 Month +5.58% +5.58% 3 Month +9.43% +9.43% 6 Month +15.43% +15.43% 1 Year +45.48% +45.48% More News Read More What's Going On With Regeneron Pharmaceuticals Stock On Friday? June 28, 2024 Via Benzinga Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma June 28, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity June 25, 2024 Via Benzinga The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 13 Experts June 24, 2024 Via Benzinga $100 Invested In This Stock 20 Years Ago Would Be Worth $10,000 Today June 20, 2024 Via Benzinga Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024 June 27, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product June 27, 2024 Via Benzinga Exposures Product Safety 3 Biotech Stocks That Could Make Your Grandchildren Rich June 27, 2024 Via InvestorPlace Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine June 26, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Peering Into Regeneron Pharmaceuticals's Recent Short Interest June 11, 2024 Via Benzinga Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry June 04, 2024 Via Benzinga Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs June 24, 2024 Via Benzinga 5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More June 24, 2024 Via Benzinga Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments June 21, 2024 Via Benzinga Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024 June 21, 2024 Via InvestorPlace Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma June 16, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market June 13, 2024 Via Benzinga Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks June 13, 2024 Via Investor's Business Daily Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club June 12, 2024 Via Investor's Business Daily Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) June 11, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside June 07, 2024 Via Benzinga Stock Split Watch: 3 Growth Stocks That Could Be Next June 07, 2024 Via The Motley Fool What's Going On With FibroGen Stock Tuesday? June 04, 2024 Via Benzinga Exposures Product Safety Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
